BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang H, Wu M, Liu H, Zhou H, Zhao Y, Geng Y, Jiang B, Zhang K, Zhang B, Han Z, Du X. Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. Front Oncol 2021;11:785102. [PMID: 34900739 DOI: 10.3389/fonc.2021.785102] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Franzese O, Graziani G. Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints. Cancers (Basel) 2022;14. [PMID: 36428727 DOI: 10.3390/cancers14225633] [Reference Citation Analysis]
2 Liao M, Beltman J, Giordano H, Harding TC, Maloney L, Simmons AD, Xiao JJ. Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib. Clin Pharmacokinet 2022;61:1477-93. [PMID: 36107395 DOI: 10.1007/s40262-022-01157-8] [Reference Citation Analysis]